64483-69-8

Basic information

• Product Name: 5-Acetyloxindole
• Synonyms: 5-ACETYLOXINDOLE;5-acetylindolin-2-one;5-acetyl-2-indolinone;1H-indol-5-yl acetate;5-Acetyl-1,3-dihydro-indol-2-one;2H-Indol-2-one,5-acetyl-1,3-dihydro-
• CAS NO: 64483-69-8
• Molecular Formula: C₁₀H₉NO₂
• Molecular Weight: 175.18
• Product Categories: Indoline & Oxindole
• Mol File: 64483-69-8.mol

Chemical Properties

• Melting Point: 225-227 °C
• Boiling Point: 418.4±45.0 °C(Predicted)
• Appearance: /
• Density: 1.228±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 13.46±0.20(Predicted)
• CAS DataBase Reference: 5-Acetyloxindole(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Acetyloxindole(64483-69-8)
• EPA Substance Registry System: 5-Acetyloxindole(64483-69-8)

Safety Data

• Hazardous Substances Data: 64483-69-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
5-Acetyloxindole is used as a key intermediate in the synthesis of various pharmaceutical compounds for its potential pharmacological activities. Its anti-inflammatory, anti-cancer, and anti-viral properties make it a valuable asset in the development of new drugs to treat a wide range of diseases and conditions.
Used in Organic Synthesis:
In the field of organic synthesis, 5-Acetyloxindole is utilized as a building block for the creation of complex organic molecules. Its reactive properties allow it to participate in various chemical reactions, enabling the synthesis of a wide array of organic compounds with diverse applications.
Used in Natural Product Synthesis:
5-Acetyloxindole is employed as a precursor in the synthesis of natural products, which are often used as a source of bioactive compounds with potential therapeutic applications. Its involvement in the synthesis of these natural products contributes to the discovery and development of novel pharmaceutical agents.
Used in Chemical Reactions:
Due to its characteristic reactive properties, 5-Acetyloxindole is used in various chemical reactions, such as acylation, alkylation, and substitution reactions. These reactions facilitate the formation of new compounds with unique chemical structures and potential applications in different industries.

Upstream product

• 59-48-3 2-oxoindole 
• 75-36-5 acetyl chloride 

Downstream Products

• 107316-17-6 1-(N-benzoylcarbamoyl)-5-acetyloxindole 
• 220991-32-2 5-ethyl-2-(2',3',5',6'-tetrafluoroanilino)-phenylacetic acid 
• 864688-87-9 (Z)-1,1'-(3-(ethoxy(phenyl)methylene)-2-oxoindoline-1,5-diyl)bis(ethan-1-one) 

Relevant articles and documents

Yb(OTf)3catalyzed [1,3]-rearrangement of 3-alkenyl oxindoles

A Yb(OTf)3catalyzed [1,3]-rearrangement of 3-alkenyl oxindoles was achieved, affording a variety of multifunctional 3-ylideneoxindoles with good yields andZ/Eselectivities (64%-89% yield, 78?:?22->99?:?1Z/E). Importantly, an operationally simple, one-pot sequential catalytic synthesis of 3-ylideneoxindoles was also developed. Additionally, a cross [1,3]-rearrangement experiment and nonracemic transformation were also carried out, which indicated a concerted rearrangement mechanism of this methodology.

Preparation method of robecoxib

The invention relates to a preparation method of robecoxib. The preparation method comprises the following steps: under the protection of inert gas, adding 5-ethylindole-2-ketone, 2, 3, 5, 6-tetrafluoroiodobenzene, a catalyst, alkali, a ligand and a solve

Discovery of a potent inhibitor of MELK that inhibits expression of the anti-apoptotic protein Mcl-1 and TNBC cell growth

Despite recent advances in molecularly directed therapy, triple negative breast cancer (TNBC) remains one of the most aggressive forms of breast cancer, still without a suitable target for specific inhibitors. Maternal embryonic leucine zipper kinase (MELK) is highly expressed in TNBC, where level of overexpression correlates with poor prognosis and an aggressive disease course. Herein, we describe the discovery through targeted kinase inhibitor library screening, and structure-guided design of a series of ATP-competitive indolinone derivatives with subnanomolar inhibition constants towards MELK. The most potent compound, 17, inhibits the expression of the anti-apoptotic protein Mcl-1 and proliferation of TNBC cells exhibiting selectivity for cells expressing high levels of MELK. These studies suggest that further elaboration of 17 will furnish MELK-selective inhibitors with potential for development in preclinical models of TNBC and other cancers.

Umbelliferone-oxindole hybrids as novel apoptosis inducing agents

In furtherance of our endeavour towards the synthesis of novel bioactive agents, a panel of (E)-3-((7-hydroxy-4-methyl-2-oxo-2H-chromen-8-yl)methylene)indolin-2-one derivatives were synthesized using diverse 5-substituted oxindoles and 7-hydroxy-4-methyl-

Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors

The present invention relates to inhibitors of protein kinases of formula I: which can be used in the treatment of various diseases, notably cancer, inflammation or disorders of the central nervous system. It also relates to pharmaceutical compositions containing the compounds according to the invention and their use in therapy.

NOVEL ALKYL-CONTAINING 5-ACYLINDOLINONES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL PRODUCTS

The invention relates to alkyl-containing 5-acylindolinones of the general formula (I), where R1 to R3 are as defined in claim 1, and to tautomers, enantiomers, diastereomers, mixtures and salts thereof with valuable pharmacological

NOVEL CYCLOALKYL-CONTAINING 5-ACYLINDOLINONES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL PRODUCTS

The invention relates to cycloalkyl-containing 5-acylindolinones of the general formula (I), where R1 to R3 are as defined in claims 1 to 6, and to tautomers, enantiomers, diastereomers, mixtures and salts thereof with valuable pharmacological properties, more particularly an inhibitory effect on protein kinases, more particularly an inhibitory effect on the activity of glycogen synthase kinase (GSK-3).

Alkyl-containing 5-acylindolinones, the preparation thereof and their use as medicaments

The present invention relates to alkyl-containing 5-acylindolinones of general formula wherein R1 to R3 are defined herein, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, which have val

Cycloalkyl - containing 5-acylindolinones, the preparation thereof and their use as medicaments

The present invention relates to cycloalkyl-containing 5-acylindolinones of general formula wherein R1 to R3 are defined as in claims 1 to 6, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibiting effect on protein kinases, particularly an inhibiting effect on the activity of glycogen synthase kinase (GSK-3).

NOVEL ARYL-CONTAINING 5-ACYLINDOLINONES, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS

The invention relates to aryl-containing 5-acylindolinones of general formula (I) in which R1 to R3 are defined as in Claims 1 to 7, the tautomers, enantiomers, diastereomers, mixtures and salts thereof, all of which having valuable